Vedolizumab was FDA approved in 2014 to treat ulcerative colitis and Crohn’s disease. What is the mechanism of action for this biologic therapy?

A. Janus kinase inhibitor  
B. Anti-α4β7 integrin antibody  
C. Sphingosine-1-phosphate receptor subtypes 1 and 5 agonist  
D. Anti interleukin-12 and interleukin-23 antibody

Answer B
Vedolizumab is an anti-α4β7 integrin antibody targeting leukocyte trafficking and was FDA approved in 2014 to treat ulcerative colitis and Crohn’s disease.